Non-alcoholic fatty liver disease

Elizabeth E. Powell*, Vincent Wai Sun Wong, Mary Rinella

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1086 Scopus citations


Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation and faster fibrosis progression than non-alcoholic fatty liver. NAFLD has a bidirectional association with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. Although the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality, and can be assessed with combinations of non-invasive tests. Patients with cirrhosis should be screened for hepatocellular carcinoma and oesophageal varices. There is currently no approved therapy for NAFLD, although several drugs are in advanced stages of development. Because of the complex pathophysiology and substantial heterogeneity of disease phenotypes, combination treatment is likely to be required for many patients with NAFLD. Healthy lifestyle and weight reduction remain crucial to the prevention and treatment of NAFLD.

Original languageEnglish (US)
Pages (from-to)2212-2224
Number of pages13
JournalThe Lancet
Issue number10290
StatePublished - Jun 5 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Non-alcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this